secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001641172-25-000514
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed
--------------------------------------------------------------------------------

- Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
- EsoGuard revenue of $1.2M for Q4; GAAP net loss $11.5M ($0.20/share); non-GAAP loss $10.9M ($0.19/share).
- Cash and equivalents $22.4M at Dec 31, 2024; pro forma ~$36.9M after Q1 2025 common stock financing.
- Secured first commercial coverage from Highmark and first state biomarker agreement with Blue Cross Blue Shield of RI.
- Completed $22M convertible debt refinancing and $15.3M stock financing, net proceeds $32.8M, extending cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000164117225000514/0001641172-25-000514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000164117225000514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer